Alan H. Auerbach Sells 33,841 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) CEO Alan H. Auerbach sold 33,841 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $106,599.15. Following the sale, the chief executive officer now directly owns 7,029,674 shares in the company, valued at $22,143,473.10. This trade represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Puma Biotechnology Stock Performance

Shares of PBYI traded down $0.17 during trading hours on Friday, hitting $2.95. The stock had a trading volume of 844,494 shares, compared to its average volume of 763,397. The firm has a market capitalization of $144.81 million, a PE ratio of 6.15 and a beta of 1.08. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. Puma Biotechnology, Inc. has a 12 month low of $2.22 and a 12 month high of $7.73. The stock has a fifty day moving average price of $2.99 and a 200 day moving average price of $2.98.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.31 by $0.10. The firm had revenue of $80.50 million during the quarter, compared to analyst estimates of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same quarter in the prior year, the firm earned $0.12 EPS. Analysts anticipate that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. StockNews.com cut shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research note on Friday, December 6th. HC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of Puma Biotechnology in a research report on Monday, December 23rd.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. American Century Companies Inc. raised its holdings in Puma Biotechnology by 98.5% in the 2nd quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company's stock worth $2,409,000 after purchasing an additional 366,653 shares during the period. Affinity Asset Advisors LLC purchased a new stake in Puma Biotechnology in the second quarter worth about $815,000. Frazier Life Sciences Management L.P. raised its stake in shares of Puma Biotechnology by 8.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company's stock worth $9,984,000 after buying an additional 246,264 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Puma Biotechnology during the 3rd quarter valued at about $627,000. Finally, Great Point Partners LLC grew its stake in shares of Puma Biotechnology by 10.6% during the 2nd quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company's stock valued at $4,846,000 after acquiring an additional 142,916 shares during the period. Hedge funds and other institutional investors own 61.29% of the company's stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.